Back to top
more

Fibrocell Science Inc (FCSC)

(Delayed Data from NSDQ)

$2.24 USD

2.24
73,296

+0.02 (0.90%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.24 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Reata Successfully Completes Neuromuscular Disorder Study

by Zacks Equity Research

Reata (RETA) rallies following the successful completion of a pivotal study evaluating omaveloxolone as a potential treatment for Friedreich's ataxia, a progressive neuromuscular disorder.

Savara Plunges on Failure of Late-Stage Study on Molgradex

by Zacks Equity Research

Savara's (SVRA) lead pipeline candidate, Molgradex, fails to meet primary endpoint in a phase III study evaluating it in a rare autoimmune lung disorder.

Fibrocell Up on FDA Designation for Gene Therapy Candidate

by Zacks Equity Research

Fibrocell's (FCSC) gene therapy for a genetic skin disorder gets Regenerative Medicine Advanced Therapy designation, which expedites development process.

Is Fibrocell Science (FCSC) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (FCSC) Outperforming Other Medical Stocks This Year?

The Zacks Analyst Blog Highlights: Limbach, Health Insurance, Fibrocell, Camden and First Business

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Limbach, Health Insurance, Fibrocell, Camden and First Business

Fibrocell (FCSC) Miss Estimates for Earnings & Revenues in Q1

by Zacks Equity Research

Fibrocell (FCSC) misses estimates for earnings and sales in the first quarter of 2019.

Nalak Das headshot

Small Business Optimism Hits 4-Month High in April: 5 Picks

by Nalak Das

Small corporates create significant amount of jobs in the U.S. economy.

Is Fibrocell Science (FCSC) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (FCSC) Outperforming Other Medical Stocks This Year?

Blueprint Medicines (BPMC) Q1 Earnings & Sales Lag Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) posts wider-than-expected loss in first-quarter while sales miss estimates.

    Global Blood (GBT) Reports Narrower-Than-Expected Loss in Q1

    by Zacks Equity Research

    Global Blood (GBT) reports narrower-than-expected loss in the first quarter of 2019.

    Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss

    by Zacks Equity Research

    Agenus' (AGEN) earnings beat estimates in the first quarter of 2019. Sales marginally miss the same.

    Spectrum Pharma (SPPI) Q1 Earnings Lag Estimates, Revenues Nil

    by Zacks Equity Research

    Spectrum Pharma (SPPI) misses bottom-line estimates in the first quarter. The company completes sale of its marketed portfolio in March.

    Puma Biotech (PBYI) Q1 Earnings Top, Nerlynx Disappoints

    by Zacks Equity Research

    Puma Biotech (PBYI) incurs narrower loss in Q1. Sales of Nerlynx fall short of expectations due to higher discontinuations. Stock plunges 32.5%.

    Intrexon (XON) Reports In-Line Q1 Loss, Misses on Revenues

    by Zacks Equity Research

    Intrexon (XON) reports in line loss in the first quarter of 2019. Also, sales miss estimates.

    Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates

    by Zacks Equity Research

    Horizon Therapeutics' (HZNP) sales beat estimates in the first quarter of 2019, primarily owing to strong performance of Krystexxa, Ravicti, Procysbi and Rayos.

    Amicus' (FOLD) Earnings & Revenues Miss Estimates in Q1

    by Zacks Equity Research

    Amicus (FOLD) reports wider-than-expected loss in the first quarter of 2019. Also, sales miss estimates.

    IVERIC bio's (ISEE) Q1 Loss Narrows, Gene Therapy in Focus

    by Zacks Equity Research

    IVERIC bio (ISEE) first-quarter earnings beat estimates. The company is focusing on developing gene therapies for treating inherited retinal diseases.

    Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up

    by Zacks Equity Research

    Sarepta (SRPT) beats estimates for both earnings and sales in first-quarter 2019. Exondys 51 continues to perform well on strong demand. Shares up.

    Arena Pharmaceuticals' (ARNA) Loss Widens in Q1 But Stock Up

    by Zacks Equity Research

    Arena Pharmaceuticals (ARNA) reports loss in the first quarter of 2019 on an adjusted basis. Revenues of $801.1 million include upfront payment of $800 million from United Therapeutics.

    AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates

    by Zacks Equity Research

    AMAG (AMAG) reports wider-than-expected loss and misses sales estimates in the first quarter of 2019.

      Mylan's (MYL) Q1 Earnings Beat Estimates, Revenues Miss

      by Zacks Equity Research

      Mylan's (MYL) earnings beat estimates but sales miss the same in the first quarter of 2019.

      Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q1

      by Zacks Equity Research

      Ultragenyx (RARE) reports wider-than-expected loss and misses sales estimates in the first quarter of 2019.

      Fibrocell Science (FCSC) Flat As Market Gains: What You Should Know

      by Zacks Equity Research

      Fibrocell Science (FCSC) closed the most recent trading day at $2.30, making no change from the previous trading session.

      Fibrocell (FCSC) Q1 Earnings: What's in Store for the Stock?

      by Zacks Equity Research

      For Fibrocell's (FCSC) Q1, investors will eye the company's progress with its gene therapy candidate, FCX-007, currently being developed for treating recessive dystrophic epidermolysis bullosa.

      Is Fibrocell Science (FCSC) Stock Outpacing Its Medical Peers This Year?

      by Zacks Equity Research

      Is (FCSC) Outperforming Other Medical Stocks This Year?